On May 17, 2017 Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies reported it will announce plans to launch or file for regulatory approval more than 10 new products with blockbuster potential between 2017 and 2021, as well as 50-plus line extensions of existing and new medicines that will bring the company’s transformational medicines to an even broader patient population (Press release, Johnson & Johnson, MAY 17, 2017, View Source [SID1234519174]). The company will also share its plans to continue driving sustainable growth by leveraging its strong portfolio of core blockbuster products, the industry-leading productivity of its innovation model, and the pending acquisition of Swiss-based biotech company Actelion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world," said Alex Gorsky, Chairman and Chief Executive Officer. "Our pharmaceutical business will continue to be a significant driver of innovation and growth for Johnson & Johnson. With our proven global commercial capabilities and robust pipeline, we are well-positioned to continue delivering strong, long-term, sustainable growth."

An industry leader in research productivity, Janssen has received US FDA approval for 11 new molecular entities (NMEs) since 2011. With a portfolio focused on five core therapeutic areas – Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism, and Oncology – the Pharmaceutical segment of Johnson & Johnson is delivering transformational new medicines for unmet medical needs worldwide, and expects to add a sixth therapeutic area in Pulmonary Arterial Hypertension upon the completion of the acquisition of Actelion, which is expected to close by the end of the second quarter.

In 2016, the company filed two NMEs that it anticipates will be approved and launched later this year:

guselkumab for psoriasis; and
sirukumab for rheumatoid arthritis.
Additional late-stage blockbuster products1 projected to file for regulatory approvals between 2017 and 2021, include:

apalutamide (ARN-509) for pre-metastatic prostate cancer;
esketamine for treatment-resistant depression;
talacotuzumab (CSL362) for acute myeloid leukemia;
erdafitinib (FGFR Inhibitor) for solid tumors;
niraparib for prostate cancer;
imetelstat for myelofibrosis;
pimodivir (JNJ-3872) for influenza A;
lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection; and,
JNJ-7922 (orexin-2 antagonist) for adjunctive treatment for major depressive disorder.